More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi (formerly STS101) has been given the go-ahead by the agency. The drug – a new dry powder ...

Following a complete response letter last year, Satsuma Pharmaceuticals Inc. received U.S. FDA approval of dihydroergotamine nasal powder to treat acute migraine with or without aura. Branded Atzumi, ...

Satsuma rallied from a Friday loss on the road to beat Bayside Academy in a doubleheader opener on Saturday and then take the Class 4A, Area 1 series tiebreaker – and the championship – with a ...

She imports almost everything: baked beans, clotted cream, teas and tea pots. “We've already had lots of emails from purveyors saying the prices are going to go up because of the tariffs ...

All products featured on Architectural Digest are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links ...

Add articles to your saved list and come back to them any time. 10am After waking up to a never-ending stream of builders at 6.30am due to renovations, it’s time for a black coffee. Try to get ...

from Loewe’s artist-designed teapots to The Row’s first home collection Paris Fashion Week A/W 2025 highlights: Chanel to Saint Laurent Wallpaper* selects the very best of Paris Fashion Week A/W 2025, ...

London is the most famous city in the world associated with a cup of tea, but which serves the best? The best brews in town have been put to the test by one man on a mission. Us Brits renowned for ...

Teas from Sloane include Oolong Crème and Peaches and Cream, poured from silver teapots in the dining room or, weather permitting, on the terrace. Feeling un peu extra? Add on Pomme, a $34 ...

The FDA has approved Satsuma’s STS101 dihydroergotamine (DHE) nasal powder under the name of Atzumi as a new treatment for adults with acute migraine, with or without aura. The approval is based on ...

Clinical-stage biopharma company Satsuma Pharmaceuticals and its corporate parent, Shin Nippon Biomedical (TYO: 2395), announced that they have received US Food and Drug Administration (FDA) approval ...